ArticleJournal of thoracic disease2025
A comprehensive analysis of antihypertensive medications and their impact on lung cancer incidence and all-cause mortality: a population-based study in South Korea.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Renin-angiotensin system inhibitor use and survival outcomes in lung cancer: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is a significant global health concern. Numerous studies have explored its etiology. There are conflicting findings on the relationship between antihypertensive medication use and development of lung cancer. This study aimed to examine associations of two widely used antihypertensive drug classes-angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs)-with risk of lung cancer and all-cause mortality. Methods: Employing data from the Korea National Health Insurance Sharing Service (January 1, 2002 to December 31, 2019, with an 8-year washout), this study concentrated on hypertensive patients prescribed ARB or CCB for ≥90 days between January 1, 2010 and December 31, 2019. Analyses included propensity score matching (PSM) and subgroup assessments. Results: This study encompassed 3,451,701 patients. Following PSM, each group had 173,531 patients. Prior to PSM, the CCB group exhibited a higher hazard ratio (HR) for lung cancer incidence than the ARB group (HR: 1.425; P<0.001). After PSM, the CCB group maintained a higher HR for lung cancer than the ARB group (HR: 1.134, P=0.02). These findings were paralleled in all-cause mortality rates, with adjusted HR analyses consistently showing higher risks in the CCB group. CCBs showed associations with higher risks across various conditions and durations of drug use in subgroup analyses. Conclusions: CCB use may increase the risk of lung cancer incidence and all-cause mortality compared with ARB use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.